Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Publication: J Clin Pharmacol

Quizartinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3-internal tandem duplication-mutated relapsed/refractory acute myeloid leukemia (AML).

Reliance: a smarter way of regulating medical products – The IPRP survey

Reliance: a smarter way of regulating medical products – The IPRP survey

Publication: Expert Rev Clin Pharmacol
Division: PBPK

A survey was conducted among national regulatory authorities' members of the International Pharmaceutical Regulators Programme (IPRP) to collect and share experiences of reliance approaches.

Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development

Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development

Publication: Drug Discov Today
Software: GastroPlus®

Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited..

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

Publication: Journal of Molecular Structure
Software: ADMET Predictor®

Osteosarcoma (OS) is a malignant bone tumor and its occurrence is associated with high levels of microRNAs (miRNAs) and critical protein involved on intracellular signaling pathways.

Computational evaluation of endocrine activity of biocidal active substances

Computational evaluation of endocrine activity of biocidal active substances

Publication: Chemosphere
Software: ADMET Predictor®

Exposure to endocrine disrupting chemicals is an important public health concern although only a few endocrine disruption chemicals have been identified so far.

A Latent Variable Approach to Account for Correlated Inputs in Global Sensitivity

A Latent Variable Approach to Account for Correlated Inputs in Global Sensitivity

Authors: Melillo N, Darwich AS
Publication: Cornell University
Software: ADMET Predictor®

In pharmaceutical research and development decision-making related to drug candidate selection, efficacy and safety...

BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide

BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide

Publication: Pharmaceutics
Software: GastroPlus®

Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet...

5-Fluorouracil Loaded Biogenic and Albumin Capped Gold Nanoparticles Using Bacterial Enzyme—In Vitro-In Silico Gastroplus® Simulation and Prediction

5-Fluorouracil Loaded Biogenic and Albumin Capped Gold Nanoparticles Using Bacterial Enzyme—In Vitro-In Silico Gastroplus® Simulation and Prediction

Publication: Processes
Software: GastroPlus®

The study investigated in situ biosynthesis of albumin capped 5-fluorouracil (5-FU) loaded gold nanoparticles (NPs) using bacterial extract for enhanced...

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations

Publication: Pharm Res
Division: PBPK

The purpose of this study is to show how the Ocular Compartmental Absorption & Transit (OCAT™) model in GastroPlus® can be used to characterize ocular...

Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket

Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket

Publication: Bioorg Med Chem
Software: ADMET Predictor®

Recently we have developed novel oxotriazinoindole inhibitors (OTIs) of aldose reductase (ALR2), characterized by high efficacy and selectivity.